In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right until disease progression or the participants are unable to tolerate the study drugs. Total, our present work highlights the potential utilization of ARV-825 in combination with https://lorenzoqcnxj.blogtov.com/12401122/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers